跳至主要内容
临床试验/NCT01872520
NCT01872520已完成不适用

Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study

Peking University Third Hospital36 个研究点 分布在 1 个国家目标入组 30,180 人开始时间: 2012年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30,180
试验地点
36
主要终点
The rare adverse drug reactions to the IDSDFSY

研究概览

简要总结

Magnesium Lithospermate B, the main constituent of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza), is the active ingredient of Salvia Miltiorrhiza. This study record clinical use of The injection of DanShenDuoFenSuanYan in the real world, and observe the adverse drug reactions/ adverse drug events during treatment.

详细描述

As a traditional chinese medicine, the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza) was approved by State Food and Drug Administration of China in May,2005. This cardiovascular drug is one of the few Traditional Chinese Medicine pharmaceuticals where the active ingredients have been identified in the molecular levels. In its 8 years marketing in China, there is no serious adverse drug reactions.

In this study, clinical pharmacists in selected hospitals will record the clinical use and the adverse drug reactions/ adverse drug events of this injection.

This real world study for the Injection of DanShenDuoFenSuanYan with 30400 patients will be conducted from June.2012 to May.2014.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in china(including the inpatient and the outpatient(only in some hospitals which can get the information)).

排除标准

  • 未提供

结局指标

主要结局

The rare adverse drug reactions to the IDSDFSY

时间窗: 3 years

The incidence of IDSDFSY induced adverse drug reaction

时间窗: 3 years

次要结局

  • The patients' characteristics who are prescribed IDSDFSY(3 years)
  • Off-label use of IDSDFSY(3 years)
  • The manifestation, treatment and outcomes of the ADRs(3 years)
  • The risk factors of the ADRs(3 years)
  • The prescribing pattern of IDSDFSY in real world clinical practice(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Suodi ZHAI

Suodi ZHAI, Department of Pharmacy, Peking University Third Hospital

Peking University Third Hospital

研究点 (36)

Loading locations...

相似试验